ETBX-061

AXP000157.1 · Cancer vaccine

Platform
adenovirus (Ad5 [E1-, E2b-])
Targets
MUC1
Originator
Etubics
Sponsor
ImmunityBio

Names

NameTypeSource
ETBX-061preferred name, codecurator, ncit
Ad5-MUC1 vaccine ambiguoussynonymncit
Adenoviral MUC1 Vaccine ETBX-061 ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 [E1-, E2b-]
Replication
non replicating
Modifications
E1 and E2b regions deleted (replication-defective, reduced late gene expression)
Transgenes
MUC1
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C143035
FDA UNII
17K7SN702N

Approvals

No regulatory approval recorded.

Clinical trials (21)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04247282Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus InfectionCompletedPhase 1/22020-06-092021-08-2421Head and Neck Cancer; Head and Neck Neoplasms
NCT03563157QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedPhase 1/22018-09-282019-04-212Colorectal Cancer Metastatic; mCRC
NCT03554109QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 22018-092020-060Triple Negative Breast Cancer (TNBC)
NCT03647423QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnPhase 1/22018-08-312020-08-310Chordoma; Unresectable Malignant Neoplasm
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 22018-082019-12-300Metastatic Pancreatic Cancer
NCT03169777QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/22018-082019-010Colorectal Cancer
NCT03481816Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy VaccinesCompletedPhase 12018-07-242020-01-1518Prostatic Cancer; Prostatic Neoplasms
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/22018-07-172019-04-173Pancreatic Cancer
NCT03574649QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 22018-062018-080Non Small Cell Lung Cancer
NCT03563170QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/22018-05-252019-08-230Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent
NCT03387085QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/22018-03-192020-09-119Triple Negative Breast Cancer
NCT03169738QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/22018-022019-010Non-small Cell Lung Cancer
NCT03384316Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerCompletedPhase 12018-01-312018-05-2211Breast Cancer; Colon Cancer; Lung Cancer; Neoplasms; Prostate Cancer
NCT03387111QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/22018-01-092019-04-174Squamous Cell Carcinoma
NCT03197584QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/22017-122019-020Ovarian Cancer
NCT03197571QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Urothelial Carcinoma
NCT03175666QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/22017-122019-010Triple Negative Breast Cancer
NCT03169790QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnPhase 1/22017-122019-010Non Hodgkin Lymphoma
NCT03169764QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Head and Neck Squamous Cell Carcinoma
NCT03167177QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Melanoma
NCT03167164QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Merkel Cell Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39944830Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.Frontiers in oncology2025name in abstract: ETBX-061
PMID 40156838Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection.The oncologist2025cited by trial NCT04247282
PMID 35727629Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.The Journal of clinical investigation2022cited by trial NCT04247282
PMID 33720067The role of the tumor matrix environment in progression of head and neck cancer.Current opinion in oncology2021cited by trial NCT04247282
PMID 33762322Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).Journal for immunotherapy of cancer2021cited by trial NCT03481816
PMID 31594913A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.The oncologist2020cited by trial NCT03384316

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: ETBX-061

Notes

Ad5 [E1-, E2b-] vector of the Etubics (now ImmunityBio) AdenoVerse-style platform, given subcutaneously; the E2b deletion is intended to allow repeat dosing despite pre-existing Ad5 immunity. Studied alone and in the multi-antigen Tri-Ad5 / 'Triad' regimens, which are combinations and not programs of their own. NCIt preferred name: Adenoviral MUC1 Vaccine ETBX-061.

How to cite

ETBX-061 (AXP000157.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000157.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.